Articles related to COGNITIVE HEALTH/MEMORY

The findings point to the possibility of very early detection of dementias, when recruitment into preventive trials, drug trials, and implementation of preventive strategies to slow the disease have the most impact.

A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.

In this study, higher levels of omega-3s were linked with larger hippocampal volumes and improved cognition, and the increases seen continually with each step measurement of the omega-3s. All measured omega-3 predictors were tied to better abstract reasoning test scores. Participants in the top three quartiles of EPA levels had better abstract reasoning performance than those in the bottom EPA quartile. The associations remained after adjusting for vascular risk factors.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

The optimal dose of daily steps—the amount with the greatest dementia risk reduction—was 9,826 steps, with the minimum step dose, or the amount at which dementia risk was half of the maximal reduction, was 3,826 steps per day. See the original article on JAMA Neurology.